Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Transl Psychiatry ; 12(1): 372, 2022 09 08.
Artigo em Inglês | MEDLINE | ID: mdl-36075922

RESUMO

The disease burden and healthcare costs of psychiatric diseases along with the pursuit to understand their underlying biochemical mechanisms have led to psychiatric biomarker investigations. Current advances in evaluating candidate biomarkers for psychiatric diseases, such as major depressive disorder (MDD), focus on determining a specific biomarker signature or profile. The origins of candidate biomarkers are heterogenous, ranging from genomics, proteomics, and metabolomics, while incorporating associations with clinical characterization. Prior to clinical use, candidate biomarkers must be validated by large multi-site clinical studies, which can be used to determine the ideal MDD biomarker signature. Therefore, identifying valid biomarkers has been challenging, suggesting the need for alternative approaches. Following validation studies, new technology must be employed to transition from biomarker discovery to diagnostic biomolecular profiling. Current technologies used in discovery and validation, such as mass spectroscopy, are currently limited to clinical research due to the cost or complexity of equipment, sample preparation, or measurement analysis. Thus, other technologies such as electrochemical detection must be considered for point-of-care (POC) testing with the needed characteristics for physicians' offices. This review evaluates the advantages of using electrochemical sensing as a primary diagnostic platform due to its rapidity, accuracy, low cost, biomolecular detection diversity, multiplexed capacity, and instrument flexibility. We evaluate the capabilities of electrochemical methods in evaluating current candidate MDD biomarkers, individually and through multiplexed sensing, for promising applications in detecting MDD biosignatures in the POC setting.


Assuntos
Transtorno Depressivo Maior , Biomarcadores , Transtorno Depressivo Maior/diagnóstico , Eletroquímica , Humanos , Metabolômica/métodos , Proteômica/métodos
2.
ACS Appl Polym Mater ; 2(11): 5086-5093, 2020 Nov 13.
Artigo em Inglês | MEDLINE | ID: mdl-34651131

RESUMO

A reusable sensor architecture, through the combination of self-assembled monolayers and cyclodextrin supramolecular interactions, is demonstrated for class recognition of hydrophobic analytes demonstrated with trans-resveratrol. The reloadable sensor is based on reversible immobilization of α-cyclodextrin on polyethylene glycol surface. α-cyclodextrins complexes with polyethylene glycols and causes the polymer chains to change their surface configuration. The reproducibility and stability of the sur-face, in the detection of nanomolar concentrations of trans-resveratrol, can be demonstrated by electrochemical impedance spectroscopy, X-ray photoelectron spectroscopy, and Attenuated total reflectance-Fourier transform infrared spectroscopy. We propose that during sensor operation, α-cyclodextrin decouples from the poly-ethylene glycol surface to complex with trans-resveratrol in solution, and after use, the surface regeneration is conducted with a simple α-cyclodextrin soak. To test the nonspecific response, the sensor was also tested with trans-resveratrol spiked human urine.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA